GlaxoSmithKline Plc and Valeant Pharmaceuticals International Inc. won U.S. approval for an epilepsy drug designed as an add-on therapy for patients who aren’t helped by current treatments.
The Food and Drug Administration cleared the medicine, chemically known as ezogabine, the companies said today in a statement. The FDA delayed a decision on the product, to be marketed as Potiga, twice last year.
